Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SVV 001

Next Previous
Drug Profile

SVV 001

Alternative Names: SVV; SVV-001 - Seneca Therapeutics

Latest Information Update: 12 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seneca Therapeutics
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Neuroendocrine tumours; Triple negative breast cancer
  • Phase I/II Carcinoid tumour; Solid tumours

Most Recent Events

  • 02 May 2025 Phase-I clinical trials in Neuroendocrine tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intratumoural) (NCT06889493)
  • 25 Mar 2025 University of Miami plans a phase I trial for Neuroendocrine tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (Intratumoral) in May 2025 (NCT06889493)
  • 03 Oct 2022 US FDA approves IND application for phase I/II trial of SVV 001 in Neuroendocrine tumors (Combination therapy)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top